teaser
Sanofi-aventis, the French pharmaceutical firm, has said it may improve its offer to buy out Genzyme if the US biotech company undertakes negotiations.
According to Dow Jones news agency, a source at the firm said the board of Sanofi-aventis is not split on whether to increase its rejected $69 (£44) offer for each share and pursue the deal.
Apparently, the Sanofi board has agreed in principle that the offer can be improved but wants Genzyme to indicate it is happy to negotiate on it.
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
No spokesman for the French firm was available for comment.
Copyright Press Association 2010
